Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-?? therapy resistant reactive amyloidosis

摘要

Incidence of reactive amyloidosis associated with rheumatic diseases is markedly decreasing1 as the presence of organ failure such as end-stage renal disease.2 However, we still encounter new cases of amyloidosis. While anti-TNF-alpha therapy may be effective in disease modifying antirheumatic drug (DMARD) resistant cases of amyloidosis, there are yet patients whose disease does not respond to that treatment.